Measuring Residual Estrogen Receptor Availability during Fulvestrant Therapy in Patients with Metastatic Breast Cancer
- 1 January 2015
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 5 (1) , 72-81
Abstract
It is unknown whether the current dose of fulvestrant, an estrogen receptor (ER) antagonist, is sufficient for maximal ER downregulation in patients with metastatic breast cancer. We performed a feasibility study to assess ER availability before and during fulvestrant. Sixteen patients with ER-positive metastatic breast cancer underwent positron emission tomography/computed tomography (PET/CT) at baseline (scan 1), day 28 (scan 2), and day 84 (scan 3) to monitor tumor [18F]fluoroestradiol (FES) uptake. Incomplete reduction in ER availability was predefined as max) of ≥1.5. In total, 131 FES-positive lesions were identified (median SUVmax of 2.9; range, 1.7–6.5). The median change in patients during fulvestrant treatment was −85% at scan 2, but varied widely (−99% to +60%). Fulvestrant reduced tumor FES uptake incompletely at scan 2 in 6 (38%) of the 16 patients, which was associated with early progression. Significance: Serial imaging of tumor estrogen uptake by FES-PET can give insight into the dose needed for ER antagonists to completely abolish ER. FES-PET showed significant residual ER availability in tumors during fulvestrant therapy in 38% of patients, which was associated with early progression. Cancer Discov; 5(1); 72–81. ©2014 AACR. This article is highlighted in the In This Issue feature, p. 1Keywords
All Related Versions
This publication has 29 references indexed in Scilit:
- Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxideBreast Cancer Research and Treatment, 2012
- Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone‐only metastasesCancer, 2011
- Practical Approach for Comparative Analysis of Multilesion Molecular Imaging Using a Semiautomated Program for PET/CTJournal of Nuclear Medicine, 2011
- Between-Patient and Within-Patient (Site-to-Site) Variability in Estrogen Receptor Binding, Measured In Vivo by 18F-Fluoroestradiol PETJournal of Nuclear Medicine, 2011
- Fluoroestradiol Positron Emission Tomography Reveals Differences in Pharmacodynamics of Aromatase Inhibitors, Tamoxifen, and Fulvestrant in Patients with Metastatic Breast CancerClinical Cancer Research, 2011
- Insights Into the Place of Fulvestrant for the Treatment of Advanced Endocrine Responsive Breast CancerJournal of Clinical Oncology, 2010
- Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast CancerJournal of Clinical Oncology, 2010
- FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0European Journal of Nuclear Medicine and Molecular Imaging, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009